J
Jean Luc Harousseau
Researcher at University of Nantes
Publications - 82
Citations - 16270
Jean Luc Harousseau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 46, co-authored 82 publications receiving 14925 citations. Previous affiliations of Jean Luc Harousseau include University of Pennsylvania & Hotel Dieu Hospital.
Papers
More filters
Journal ArticleDOI
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Thierry Facon,Jean Yves Mary,Cyrille Hulin,Lotfi Benboubker,Michel Attal,Brigitte Pegourie,Marc Renaud,Jean Luc Harousseau,Gaelle Guillerm,Carine Chaleteix,Mamoun Dib,Laurent Voillat,Hervé Maisonneuve,Jacques Troncy,Véronique Dorvaux,Mathieu Monconduit,Claude Martin,Philippe Casassus,Jérôme Jaubert,H. Jardel,Chantal Doyen,Brigitte Kolb,Bruno Anglaret,Bernard Grosbois,Ibrahim Yakoub-Agha,Claire Mathiot,Hervé Avet-Loiseau +26 more
TL;DR: The results of this trial provide strong evidence to indicate that the use of thalidomide in combination with melphalan and prednisone should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma.
Journal ArticleDOI
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
Robert Z. Orlowski,Arnon Nagler,Pieter Sonneveld,Joan Bladé,Roman Hájek,Andrew Spencer,Jesús F. San Miguel,Tadeusz Robak,Anna Dmoszynska,Noemi Horvath,Ivan Spicka,Heather J. Sutherland,Alexander Suvorov,Sen H. Zhuang,Trilok V. Parekh,Liang Xiu,Zhilong Yuan,Wayne Rackoff,Jean Luc Harousseau +18 more
TL;DR: PLD with bortzomib is superior to bortezomib monotherapy for the treatment of patients with relapsed or refractory multiple myeloma, and the combination therapy is associated with a higher incidence of grade 3/4 myelosuppression, constitutional symptoms, and GI and dermatologic toxicities.
Journal ArticleDOI
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
François Guilhot,Claude Chastang,Mauricette Michallet,A. Guerci,Jean Luc Harousseau,Frédéric Maloisel,R. Bouabdallah,Denis Guyotat,Cheron N,Franck E. Nicolini,JF Abgrall,Tanzer J +11 more
TL;DR: The combination of interferon and cytarabine, as compared withinterferon alone, increases the rate of major cytogenetic response and prolongs survival in patients with the chronic phase of chronic myelogenous leukemia.
Journal ArticleDOI
Proteasome inhibitors in multiple myeloma: 10 years later.
Philippe Moreau,Paul G. Richardson,Michele Cavo,Robert Z. Orlowski,Jesuś F. San Miguel,Antonio Palumbo,Jean Luc Harousseau +6 more
TL;DR: An overview of the role of PIs in the treatment of MM, focusing on developments over the past decade, is provided, including carfilzomib, marizomIB, and MLN9708, and trials investigating these "second-generation" PI in patients with relapsed/refractory MMs have demonstrated positive results.
Journal ArticleDOI
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
Brian G.M. Durie,Robert A. Kyle,Andrew Belch,William I. Bensinger,Joan Bladé,Mario Boccadoro,J. Anthony Child,Raymond L. Comenzo,Ben Djulbegovic,Dorotea Fantl,Gösta Gahrton,Jean Luc Harousseau,Vania Hungria,Douglas E. Joshua,Heinz Ludwig,Jayesh Mehta,Angelina Rodrique Morales,Gareth J. Morgan,Amara Nouel,Martin M. Oken,R. L. Powles,David Roodman,Miquel Jesus Fernando San,Kazuyuki Shimizu,Seema Singhal,Bhawna Sirohi,Pieter Sonneveld,Guido Tricot,Brian G Van Ness +28 more
TL;DR: These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation to be international in scope, plus provide recommendations for both clinical practice and research approaches.